12:00 AM
 | 
Oct 20, 2014
 |  BioCentury  |  Emerging Company Profile

Rogne: Penetrating peptides

Rogne developing topical peptide targeting IL-23 for mild to moderate psoriasis

Rogne Bioscience Inc. is developing a topical formulation of a naturally occurring human peptide that inhibits production of inflammatory cytokines to treat mild to moderate psoriasis without the side effects of topical steroids or injectable biologics.

The 90% of psoriasis patients with mild to moderate disease are typically treated with topical steroids or vitamin D. The latter is slow to take effect and has low efficacy. Topical steroids are effective but are used episodically due to side effects such as skin atrophy. Stopping therapy frequently leads to flares.

According to Rogne President and CEO Lena Wu, about 75% of mild to moderate psoriasis patients experience treatment failure.

Use of systemic anti-TNF alphas and anti-IL-23s is restricted to severe psoriasis because the drugs are expensive and can cause chronic immunosuppression that makes patients more susceptible to serious infections.

Rogne's RON2315 is a formulation of a 15-amino-acid sequence from chemerin. While chemerin typically activates inflammation, the peptide sequence is...

Read the full 780 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >